Avacopan — Time to Replace Glucocorticoids?
In recent decades, substantial advances in the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis have led to a decrease in disease-related morbidity and mortality. The regimen for inducing remission in patients with severe ANCA-associated vasculitis has evolved on the bas...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-02, Vol.384 (7), p.664-665 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 665 |
|---|---|
| container_issue | 7 |
| container_start_page | 664 |
| container_title | The New England journal of medicine |
| container_volume | 384 |
| creator | Warrington, Kenneth J |
| description | In recent decades, substantial advances in the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis have led to a decrease in disease-related morbidity and mortality. The regimen for inducing remission in patients with severe ANCA-associated vasculitis has evolved on the basis of data from randomized clinical trials and typically consists of a tapering course of glucocorticoids in combination with cyclophosphamide or rituximab.
1
Despite these advances, glucocorticoids have remained an anchoring medication in updated regimens, and they contribute to treatment-related toxic effects. Along with evaluation of the efficacy and safety of newer agents such as rituximab, there has been a drive to . . . |
| doi_str_mv | 10.1056/NEJMe2033621 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2491072703</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2491072703</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-646a6e0d5659a781c01b15ed430d65437ac0a404ec923875bb3816943a2ec04a3</originalsourceid><addsrcrecordid>eNpt0MFKw0AQBuBFFK3Vm2cJ6MGD0dnM7iY5SSm1KlVB6jlsNlNISbIxmwjefAif0CcxpVVEnMtcPn5mfsaOOFxwkOryYXJ3TwEgqoBvsQGXiL4QoLbZACCIfBHGuMf2nVtCP1zEu2wPUcYKFR8wf_Sqja115X2-f3jzvCSvtd4T1YU25E2LzlhjmzY3Ns_c1QHbWejC0eFmD9nz9WQ-vvFnj9Pb8WjmGxRR6yuhtCLIpJKxDiNugKdcUiYQMiUFhtqAFiDIxAFGoUxTjLiKBeqADAiNQ3a2zq0b-9KRa5Myd4aKQldkO5cEIuYQBmH_9ZCd_KFL2zVVf91KgephBL06XyvTWOcaWiR1k5e6eUs4JKsak9819vx4E9qlJWU_-Lu3HpyuQVm6pKJl-X_OF1WodOM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2490691080</pqid></control><display><type>article</type><title>Avacopan — Time to Replace Glucocorticoids?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Warrington, Kenneth J</creator><creatorcontrib>Warrington, Kenneth J</creatorcontrib><description>In recent decades, substantial advances in the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis have led to a decrease in disease-related morbidity and mortality. The regimen for inducing remission in patients with severe ANCA-associated vasculitis has evolved on the basis of data from randomized clinical trials and typically consists of a tapering course of glucocorticoids in combination with cyclophosphamide or rituximab.
1
Despite these advances, glucocorticoids have remained an anchoring medication in updated regimens, and they contribute to treatment-related toxic effects. Along with evaluation of the efficacy and safety of newer agents such as rituximab, there has been a drive to . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMe2033621</identifier><identifier>PMID: 33596361</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Aniline Compounds ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ; Antineutrophil cytoplasmic antibodies ; Clinical trials ; Cyclophosphamide ; Glucocorticoids ; Humans ; Immunotherapy ; Infections ; Monoclonal antibodies ; Morbidity ; Nipecotic Acids ; Patients ; Quality of life ; Remission ; Rituximab ; Vasculitis</subject><ispartof>The New England journal of medicine, 2021-02, Vol.384 (7), p.664-665</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-646a6e0d5659a781c01b15ed430d65437ac0a404ec923875bb3816943a2ec04a3</citedby><cites>FETCH-LOGICAL-c348t-646a6e0d5659a781c01b15ed430d65437ac0a404ec923875bb3816943a2ec04a3</cites><orcidid>0000-0001-7708-2487</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMe2033621$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2490691080?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2758,2759,26102,27923,27924,52381,54063,64384,64386,64388,72340</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33596361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Warrington, Kenneth J</creatorcontrib><title>Avacopan — Time to Replace Glucocorticoids?</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In recent decades, substantial advances in the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis have led to a decrease in disease-related morbidity and mortality. The regimen for inducing remission in patients with severe ANCA-associated vasculitis has evolved on the basis of data from randomized clinical trials and typically consists of a tapering course of glucocorticoids in combination with cyclophosphamide or rituximab.
1
Despite these advances, glucocorticoids have remained an anchoring medication in updated regimens, and they contribute to treatment-related toxic effects. Along with evaluation of the efficacy and safety of newer agents such as rituximab, there has been a drive to . . .</description><subject>Aniline Compounds</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</subject><subject>Antineutrophil cytoplasmic antibodies</subject><subject>Clinical trials</subject><subject>Cyclophosphamide</subject><subject>Glucocorticoids</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Infections</subject><subject>Monoclonal antibodies</subject><subject>Morbidity</subject><subject>Nipecotic Acids</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Remission</subject><subject>Rituximab</subject><subject>Vasculitis</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0MFKw0AQBuBFFK3Vm2cJ6MGD0dnM7iY5SSm1KlVB6jlsNlNISbIxmwjefAif0CcxpVVEnMtcPn5mfsaOOFxwkOryYXJ3TwEgqoBvsQGXiL4QoLbZACCIfBHGuMf2nVtCP1zEu2wPUcYKFR8wf_Sqja115X2-f3jzvCSvtd4T1YU25E2LzlhjmzY3Ns_c1QHbWejC0eFmD9nz9WQ-vvFnj9Pb8WjmGxRR6yuhtCLIpJKxDiNugKdcUiYQMiUFhtqAFiDIxAFGoUxTjLiKBeqADAiNQ3a2zq0b-9KRa5Myd4aKQldkO5cEIuYQBmH_9ZCd_KFL2zVVf91KgephBL06XyvTWOcaWiR1k5e6eUs4JKsak9819vx4E9qlJWU_-Lu3HpyuQVm6pKJl-X_OF1WodOM</recordid><startdate>20210218</startdate><enddate>20210218</enddate><creator>Warrington, Kenneth J</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7708-2487</orcidid></search><sort><creationdate>20210218</creationdate><title>Avacopan — Time to Replace Glucocorticoids?</title><author>Warrington, Kenneth J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-646a6e0d5659a781c01b15ed430d65437ac0a404ec923875bb3816943a2ec04a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aniline Compounds</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</topic><topic>Antineutrophil cytoplasmic antibodies</topic><topic>Clinical trials</topic><topic>Cyclophosphamide</topic><topic>Glucocorticoids</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Infections</topic><topic>Monoclonal antibodies</topic><topic>Morbidity</topic><topic>Nipecotic Acids</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Remission</topic><topic>Rituximab</topic><topic>Vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Warrington, Kenneth J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Warrington, Kenneth J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Avacopan — Time to Replace Glucocorticoids?</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-02-18</date><risdate>2021</risdate><volume>384</volume><issue>7</issue><spage>664</spage><epage>665</epage><pages>664-665</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In recent decades, substantial advances in the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis have led to a decrease in disease-related morbidity and mortality. The regimen for inducing remission in patients with severe ANCA-associated vasculitis has evolved on the basis of data from randomized clinical trials and typically consists of a tapering course of glucocorticoids in combination with cyclophosphamide or rituximab.
1
Despite these advances, glucocorticoids have remained an anchoring medication in updated regimens, and they contribute to treatment-related toxic effects. Along with evaluation of the efficacy and safety of newer agents such as rituximab, there has been a drive to . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>33596361</pmid><doi>10.1056/NEJMe2033621</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-7708-2487</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-02, Vol.384 (7), p.664-665 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2491072703 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Aniline Compounds Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antineutrophil cytoplasmic antibodies Clinical trials Cyclophosphamide Glucocorticoids Humans Immunotherapy Infections Monoclonal antibodies Morbidity Nipecotic Acids Patients Quality of life Remission Rituximab Vasculitis |
| title | Avacopan — Time to Replace Glucocorticoids? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T07%3A25%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Avacopan%20%E2%80%94%20Time%20to%20Replace%20Glucocorticoids?&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Warrington,%20Kenneth%20J&rft.date=2021-02-18&rft.volume=384&rft.issue=7&rft.spage=664&rft.epage=665&rft.pages=664-665&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMe2033621&rft_dat=%3Cproquest_cross%3E2491072703%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2490691080&rft_id=info:pmid/33596361&rfr_iscdi=true |